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Simple Summary: Hepatoblastoma (HB), the most common form of childhood liver cancer, is
associated with dual mutation and/or dysregulation of the Wnt/β-catenin and Hippo pathways in
~50% of cases. However, this mutational simplicity cannot explain HB’s biological and histologic
diversity. This discussion focuses upon recent work showing that specific β-catenin mutants are
key determinants of this HB variability as well as their metabolic and transcriptional signatures.
Dysregulation of the anti-oxidant NFE2L2 pathway also contributes to tumorigenesis by being
directly transforming in association with either of the other two factors. The transcriptional overlap
of tumors generated by pairs of factors identifies crucial targets that likely mediate HB tumorigenesis,
behavior and appearance.
Abstract: Hepatoblastoma (HB), the most common childhood liver cancer, is associated with seven
distinct histologic subtypes and variable degrees of clinical aggressiveness and presentation. Yet it
is among the least genomically altered tumors known, with about half of HBs showing mutation
and/or dysregulation of the Wnt/β-catenin and Hippo pathways. This raises the question of how this
mutational simplicity can generate such biological and histologic complexity. Recent work shows that
the identity of the underlying β-catenin mutation is a major contributor. Mutation or over-expression
of the NFE2L2/NRF2 transcription factor, previously thought only to promote anti-oxidant responses,
has also recently been shown to accelerate the growth of HBs generated by mutations in the Wnt/β-
catenin and Hippo pathways while imparting novel features such as the tumor-associated cysts
and necrosis. Moreover, patient-associated NFE2L2 mutations are overtly transforming when co-
expressed with either mutant β-catenin or a Hippo pathway effector. The finding that tumorigenesis
can be driven by any two arms of the β-catenin/Hippo/NFE2L2 axis has permitted the identification
of a small subset of coordinately regulated tumor-specific transcripts, some of whose levels correlate
with inferior long-term outcomes in HB and other cancers. Collectively, these findings begin to
provide for more refined and molecularly based classification, survival algorithms and design of
chemotherapeutic regimens.
Keywords: β-catenin; hepatocellular carcinoma; Hippo pathway; liver cancer; NFE2L2; NRF2;
plasminogen activator inhibitor-1 (PAI-1); Serpin E1
1. Introduction
Hepatoblastoma (HB) is a rare pediatric tumor that nonetheless constitutes the
most common primary liver malignancy of childhood [1–5]. With an incidence of
about 1–2 cases/million, only about 50–70 new cases are reported each year in the United
States with a similar incidence in the European Union [6–8]. Virtually all HBs occur
in children <4–5 years of age and the majority appear before 18 months [2,3,5]. Overall
survival is approximately 70%, but this is highly dependent upon disease stage and
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histologic subtype at the time of presentation as well as other features such as patient age
and level of serum α-fetoprotein [1,3,4]. Localized Stage I disease is highly curable with
surgery alone, whereas survival of those with metastatic or recurrent disease is considerably
worse, despite the employment of the most aggressive regimens of combined modality
therapy [1,3–5].
While the vast majority of HB arises sporadically, several predisposing factors have
been identified and include prematurity, Beckwith–Wiedemann syndrome and familial
adenomatous polyposis (FAP), with disease incidence in the latter group being as much as
5000-fold higher. The increased diagnosis of HB over the past 2–3 decades likely reflects
the improved survival of low-birth-weight infants [1,4,9,10].
At least seven distinct histologic subtypes of HB have been identified with some
of these being associated with differences in long-term survival (Table 1) [5,11]. Further
complicating this is that different regions of the same tumor may display different histologic
features and, in some cases, may resemble hepatocellular carcinoma (HCC) [5].
Table 1. Histologic classification of hepatoblastoma (adopted from references [3,5]).
Type Subtype and/or Properties
Epithelial
Fetal
• Well-differentiated: uniform with round nuclei, cords with minimal mitotic activity; may be
associated with EMH *
• Crowded: mitotically active, prominent nucheoli
• Pleomorphic: poorly differentiated, high nuclear:cytoplasmic ratio; moderate anisonucleosis
• Anaplastic: marked nuclear enlargement, pleomorphism and hyperchromosia; abnormal mitoses
Embryonal Smaller cells; high nuclear:cytoplasmic ratio; primitive tubules may be associated with EMH
Macrotrabecular Fetal or embryonal type growing in clusters of 5 or more cells between sinusoids
Small cell undifferentiated About half the size of fetal HB; minimal pale & amphophillic cytoplasm; oval/round nuclei; finechromatin; inconspicuous nucleoli
Cholangioblastic Presence of bile ducts that may be quite prominent
Mixed
Stromal derivative Spindle cells/blastema; presence of other components (osteoid, cartilage, muscle)
Teratoid Mixed; primitive endoderm; presence of neural derivatives; squamous and/or glandularcomponents, melanin
* EMH: extramedullary hematopoiesis.
Most pediatric tumors are associated with far fewer driver mutations than adult
tumors, and HBs are the least mutationally diverse of all [2,12,13]. However, approximately
70% of HBs are associated with mutations in the β-catenin transcription factor and a
somewhat smaller fraction (~50–60%) of tumors show evidence for dysregulation of the
Hippo signaling pathway [2,14,15]. This raises the question of how it is possible to achieve
such clinical and histopathologic diversity given the apparent lack of driver mutation
variability. A second question is, since no more than about half of HBs deregulate both of
these pathways concurrently, what are the drivers in the remaining HBs? In this review, I
discuss recent work that has addressed these apparent paradoxes.
2. The Molecular Underpinnings of HB
The β-catenin mutations associated with HB, as well as numerous other human cancer
types, are highly variable, ranging from missense point substitutions to in-frame deletions
as large as 90 amino acids [2,16–20]. This is somewhat unusual given that most oncoprotein
mutations are more restricted and predictable by virtue of their being confined to a small
number of sites such as codons 12 or 13 in KRAS and codon 600 in BRAF [21–23]. The com-
mon and most-studied functional consequence of these heterogeneous β-catenin mutations
is to abrogate the normal Wnt-responsive cytoplasmic association between β-catenin and
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the APC complex such that β-catenin is rendered Wnt-independent and stabilized rather
than being phosphorylated by APC and rapidly degraded by the proteasome [2,16,17,20,24].
This allows β-catenin to translocate to the nucleus where it interacts with members of the
Tcf/Lef family of transcription factors and activates a suite of genes that drive proliferation
such as cyclin D and c-Myc [2,18,25]. The increased risk of HB in individuals with FAP [26]
derives from the inheritance of germ-line mutations of APC that prevent its fully engaging
with wild-type (WT) β-catenin in its normal cytoplasmic location. Thus, the primary
oncogenic determinant of β-catenin appears to be not whether it is mutated but whether it
can be stabilized and constitutively localized to the nucleus in a Wnt-independent man-
ner [17,19,24,27]. Indeed, individuals with FAP retain expression of WT, nuclearly localized
β-catenin and, as adults, develop colorectal cancer (CRC) with a frequency approaching
100% regardless of whether or not they develop HB as children [26]. Additionally, the
majority of sporadic CRCs contain acquired APC mutations, thus providing molecular
links between the sporadic and familial forms of HB and CRC [28].
The precise nature of Hippo pathway dysregulation in HB remains obscure, but its
common denominator appears to involve an inability to phosphorylate and degrade the
Hippo effector YAP (yes-associated protein) in the cytoplasm [25,29]. Echoing the β-catenin
theme, stabilized YAP translocates to the nucleus where it interacts with members of the
TEAD transcription factor family and co-activates target genes such as Cyr61, Jag1 and
Survivin while also cross-talking with the β-catenin/Tcf complex and co-regulating a
subset of its targets [18,25,29]. A key discovery was made in 2014 when Tao et al. [30]
demonstrated that hydrodynamic tail vein injection (HDTVI) into mice of Sleeping Beauty
vectors encoding the patient-derived β-catenin deletion mutant “∆(90)” and the nuclearly
localized YAP mutant “YAPS127A” efficiently induced the rapid growth of tumors that
histologically resembled the so-called crowded fetal (CF) HB subtype.
3. Accounting for HB’s Clinical and Histopathological Variability
The β-catenin mutational heterogeneity among human HBs [2,16–20] prompted
Zhang et al. [20] to ask whether this might account for their highly variable clinical behav-
iors and histologies. They generated 13 different patient-derived mutants of β-catenin,
including ∆(90), and introduced these along with YAPS127A into the livers of recipient mice
using HDTVI. They also introduced WT β-catenin to test the hypothesis that it was also
potentially transforming so long as sufficient levels were present to overwhelm APC’s
capacity for maintaining cytoplasmic confinement. To test whether all β-catenin mutants
were oncogenic, this collection included several that, while associated with other cancers,
had never been previously described in HB.
Zhang et al. made several pertinent observations that addressed the above ques-
tions [20]. First, highly efficient tumorigenesis was observed in all groups, indicating that,
at least for the mutations tested, the tumorigenicity of β-catenin mutants was not tissue-
restricted. Second, tumors grew at distinct rates, thereby allowing the 14 different groups
to be classified into three categories with median survivals of 87.4 ± 6.9 days (Group 1),
124.1 ± 6.1 days (Group 2) and 210.2 ± 17.7 days (Group 3). Third, even small differences
in β-catenin mutant identities could be associated with large phenotypic differences, as
was seen with missense mutations within the same codon. For example, tumors generated
by the S33A and S33Y mutants were associated with Groups 1 and 3, respectively, as were
those generated by the S45A and S45P mutants. From these findings, Zhang et al. [20]
concluded that β-catenin mutational variability was at least partially responsible for the
differential growth rates of human HBs. Finally, WT β-catenin was also oncogenic despite
being expressed at relatively low levels relative to endogenous β-catenin.
β-catenin mutational status also markedly impacted tumor histology in ways that
were independent of growth rate. For example, rapidly growing Group I tumors arising in
the S45A and ∆(90) mutant backgrounds showed the CF appearance typical of the most
common human HB subtype [2,3,5,20,31]. In contrast, tumors arising in response to WT
β-catenin (Group III) and the K335I point mutant (Group I) more closely resembled HCC,
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with the former containing scattered areas with CF-like HB appearance and the latter more
closely resembling the so-called blastemal-like subtype [5,11]. Group II tumors appeared to
be the most variable, ranging from those with predominant HCC-like histology (generated
by the T41A mutant) to those with a mixed histology comprised of macrotrabecular,
pleomorphic fetal and blastemal elements (generated by the S45P mutant). While the
number of mutants studied was too small to allow for general conclusions linking tumor
growth rates to particular subtypes, these findings did underscore the general idea that
particular histologic subtypes and tumor growth rates were recurrent and a predictable
outcome of the aberrant expression of certain β-catenin mutants.
4. Different β-Catenin Mutants Are Associated with Differential Subcellular
Localization and Biochemical and Molecular Behaviors Features
Zhang et al. [20] next explored whether differential tumor growth rates and ap-
pearances were attributable to altered behaviors of the β-catenin mutations. Among the
non-mutually exclusive possibilities they considered were changes in β-catenin’s stability,
which could be intrinsic in nature or due to its residual association with the APC complex
that still permitted some variable degree of β-catenin phosphorylation and proteasome-
mediated degradation [14,24,32]. They also considered different efficiencies of β-catenin’s
nuclear translocation, its transcriptional activation potential and its gene expression pro-
files. Zhang et al. [20] found large differences in the absolute levels of mutant β-catenin
expression. As expected for a protein that remained fully capable of interacting with and
being phosphorylated by APC, WT β-catenin was expressed at low levels and tumors grew
slowly, as mentioned above. On the other hand, the S33A and K335I β-catenin mutants
were also expressed at low levels yet generated Group I tumors. In keeping with this theme,
tumors expressing the highest β-catenin levels, such as S33Y, R582W and ∆(45–58) often
grew at intermediate or even slow rates (Groups II and III). Thus, wide variations in each
mutant’s stability were observed, but correlated poorly with tumor growth rates and not at
all with histology.
In light of the above findings, Zhang et al. [20] examined several other properties of
the different β-catenin mutants. Subcellular fractionation studies showed that the efficiency
of nuclear localization ranged from >95% in the case of ∆(45–58) to only about 40% for
S37A and ∆(20–32). Transient transfections performed in HEK293 cells to assess each
mutant’s ability to activate a reporter vector bearing tandem repeats of a β-catenin/Tcf4
binding site in its promoter showed wide variations in response, with WT β-catenin and
R582W being ~tenfold less efficient than the most active mutant, ∆(36–53). Yet, despite
these widely differing behaviors, all three β-catenin variants generated slowly growing
tumors. Notably, tumors generated by WT β-catenin and ∆(36–53) expressed similarly
low levels of their respective β-catenin protein and localized about equal fractions of their
proteins to the nucleus, despite demonstrating the largest differences in reporter activation.
Taken together, these results suggested that the relationships among β-catenin’s subcellular
location, inherent transactivation potential and influence over tumor growth rates and
histology were complex and probably multi-factoral.
Another possible explanation for some of the above differences arose from the obser-
vation that the slowly growing neoplasms generated by WT β-catenin actually grew at
the same rate as Group I tumors once they were established but showed a much longer
lag phase. This suggested the possibility that only a subset of transduced hepatocytes
was susceptible to transformation by WT β-catenin and further suggested that secondary
events were necessary to initiate tumor growth. Zhang et al. [20] tested this by delivering
a co-equal mix of WT β-catenin and ∆(90). Because each β-catenin was fused to differ-
ent epitope tags, they could be readily distinguished. These tumors appeared rapidly,
thereby indicating that they were driven primarily, if not exclusively, by ∆(90). More-
over, the vast majority of WT β-catenin in these tumors was now found in the cytoplasm.
This provided compelling support for the idea that tumors arising in response to WT
β-catenin dysregulation originate in a subset of transfected cells that allow for its higher
nuclear concentrations.
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Nine of the 14 tumor groups were examined by RNAseq for gene expression dif-
ferences, which ranged from 6820 to 4222 relative to control livers. Inter-tumor group
differences ranged from as many as 1515 to as few as only one. Functional categorization
of the differentially expressed transcripts among the various tumors groups indicated that
the most generally impacted pathways were those pertaining to peroxisomal-basedω-fatty
acid oxidation (FAO), lipid and xenobiotic metabolism and to several mitochondrial-based
metabolic pathways including the TCA cycle, β-FAO and branched chain amino acid
oxidation. Examination of a previously described 613 member set of direct Tcf4/β-catenin
target genes identified by ChIP-seq in primary murine hepatocytes [33] showed an av-
erage of 53% of these to be deregulated in tumors relative to livers (range 44.4–61.0%).
Collectively, these results indicated that tumors arising as a consequence of the enforced
expression of different β-catenin mutants dysregulate distinct but substantially overlap-
ping members of a large gene set, many of which are direct targets. Each tumor group’s
phenotypes and behaviors thus appear to reflect the integrated expression of its specific
gene expression profile.
Among β-catenin’s most prominent direct targets is the myc gene, whose encoded
protein, Myc, is a potent transcription factor in its own right and whose dysregulation in HB
initiates its own separate transcriptional cascade [18,34–36]. Conditional inactivation of myc
in murine hepatocytes markedly impairs HB growth and alters other behaviors in response
to the enforced co-expression of ∆(90) and YAPS127A [35–37]. Zhang et al. [20] demonstrated
that 32.2–43.6% of a >600 member set of direct Myc target genes were dysregulated in
response to the above nine WT and mutant β-catenin proteins, thus likely identifying
additional factors that contribute to tumor heterogeneity. Myc itself, normally expressed at
barely detectable levels in liver [38], was also variably up-regulated by tumors in each of
the above groups. L-Myc, which is expressed at high levels in livers, is much less active
than Myc as a transcriptional activator and imparts different phenotypes [35,36,39,40], was
variably down-regulated in tumors.
Collectively, the findings of Zhang et al. [20] indicate that the underlying β-catenin
mutation’s identity plays a preeminent role in determining many of the features of HB,
including, most notably, the rate of tumor growth, the histopathologic appearance of the
tumor and its transcriptional repertoire. These findings further suggest that knowledge of
the β-catenin mutant’s identity might be used to gauge tumor aggressiveness and potential
for recurrence and might aid in the design of more personalized therapies. Lastly, the find-
ings underscored the significant degree to which seemingly subtle mutational differences,
even within the same codon, can influence tumor behavior in profound ways. Similar
examples of the impact of seemingly minor mutational differences and their relationship to
chemotherapy response and/or survival have been described for the epidermal growth fac-
tor receptor in non-small-cell lung cancer, KRAS in CRC and PIK3CA and MAP2K(MEK1)
in other cancers [16,41–47].
5. HB Pathogenesis May Involve Culprits Other than β-Catenin and the Hippo Pathway
Given that ~80% of HBs harbor β-catenin mutations and a somewhat smaller fraction
deregulate the Hippo pathway [2,3,14,18,30,34], it remains the case that at least half of HBs
do not possess this pro-oncogenic combination. Cases of HB with FAP-associated APC
mutations or mutations in other APC Complex components such as Axin1 and Axin2 are
exceedingly rare and likely account for <2–5% of these remaining tumors [28]. Thus, other
pathways must exist to explain this gap.
Wang et al. [48] recently investigated the role of the oxidant-responsive transcription
factor NFE2L2/NRF2 (NFE2L2) in the pathogenesis of this large non-canonical subset of
HBs. Again following a theme that recalls the regulation of β-catenin and YAP, NFE2L2 is
normally maintained in an inactive cytoplasm complex with Kelch-like ECH-associated
protein 1 (KEAP1), which mediates NFE2L2’s rapid proteasome-mediated decay so as to
ensure its low-level basal expression and transcriptional quiescence [49]. In response to
oxidative or electrophilic stress, however, multiple KEAP1 cysteine residues are oxidized,
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causing the release, stabilization and nuclear translocation of NFE2L2, which, upon inter-
acting with members of the small bZIP Maf family, alters the expression of several hundred
target genes and mediates an anti-oxidant response [49–51]. An average of 4.6% of HBs,
(range 0–9.8%) harbor missense mutations in one of NFE2L2’s two KEAP1-interacting do-
mains, which leads to NFE2L2’s stabilization and nuclear localization even in the absence of
any exogenous stress [19,48,52–54]. Additionally, as many as 20% of certain adult epithelial
neoplasms and 50% of HBs amplify the WT NFE2L2 gene at 2q32.1 and allow its encoded
protein to stoichiometrically override the KEAP1 checkpoint [19,48,55,56]. It has been
proposed that, depending on when during tumorigenesis NFE2L2 dysregulation occurs,
it can either suppress or facilitate tumorigenesis. For example, at early times, NFE2L2
activation can protect against oxidant-mediated DNA damage and the accumulation of
oncogenic lesions and thus serve as a tumor suppressor [49–51]. At later times, NFE2L2
over-expression can increase the tolerance for high levels of oncogene-mediated reactive
oxygen species, thus allowing for previously unachievable levels of oncoprotein expression
and more robust aberrant signaling [51–53,55,57].
Employing the above murine HB model, Wang et al. showed that the enforced co-
expression of ∆(90) and YAPS127A, and either of two patient-derived point-mutant forms
of NFE2L2 (L30P or R34P [L30P/R34P]), but not WT NFE2L2, generated HBs that grew
significantly more rapidly than Group I tumors [20,48]. Additionally, these tumors con-
tained large and widespread areas of necrosis and innumerable fluid-filled cysts, neither
of which had been observed in the tumors previously described by Zhang et al. or oth-
ers [2,20,30,35,36], although cysts are occasionally observed in human HBs (Figure 1) [58].
Consistent with the anti-oxidant function of NFE2L2 [49–51], tumor cells expressing either
L30P or R34P and exposed briefly to H2O2 in vitro recovered from the oxidative stress
much more rapidly than either control ∆(90) + YAPS127A tumors or those co-expressing
WT NFE2L2 [48]. A similar acceleration of growth by either L30P or R34P was seen in
conjunction with the R582W β-catenin mutation that generated Group III tumors [20].
These L30P/R34P-expressing tumors now grew about as rapidly as Group I tumors and
were also associated with cysts and necrosis, thus arguing that these features were not a
consequence of an excessive growth rate that allowed the tumors to outstrip their vascular
supply. Rather, cyst formation seemed to represent an intrinsic property of the tumors
imparted by the specific co-expression of L30P/R34P.




Figure 1. The co-expression of Δ(90) β-catenin, YAPS127A and L30P/R34P induces HBs with wide-
spread cyst formation and necrosis. Low power (5×) images of H&E stained tumor HBs. The left 
panel shows the typical crowded fetal-like appearance associated with the co-expression of Δ(90) 
β-catenin and YAPS127A [20,30,35]. The right panel shows a tumor generated by the combined over-
expression of Δ(90) β-catenin + YAPS127A + R34P. Note the cysts and adjacent regions of widespread 
necrosis (asterisk). See [48] for additional, higher-power H&E-stained images of the crowded fetal 
morphology (Reprinted with permission from ref. [48]. Copyright 2021 Children’s Hospital of 
Pittsburgh of UPMC). 
Wang et al. [48] made several sassumptions in further refining the BYN subset to its 
most basic core elements. First, they eliminated 12 transcripts that were not always dereg-
ulated in the same direction in all tumor groups. An additional seven were eliminated as 
they were not deregulated in all tumors generated from the β-catenin mutants studied by 
Zhang et al. [20] or in an independently derived set of slowly growing Δ(90) + YAPS127A 
HBs generated in mice with hepatocyte-specific knockout of myc and/or the myc-related 
transcription factor chrebp [35,36]. The remaining 22 transcripts were thus posited to en-
code a common set of factors mediating transformation but having little relevance to tu-
mor initiation or growth rates, histology or specific metabolic signatures. 
Several features of the above 22 transcripts supported the notion that they were 
highly relevant to HB pathogenesis. First, ten transcripts perfectly identified a high-risk 
category of human HBs that had been previously stratified by two other groups based on 
expression differences of 16 or four transcript sets [43,56]. None of the three gene sets 
contained any common elements, thereby suggesting that the combined group of 30 tran-
scripts might be particularly useful for HB prognostication. Second, using data from The 
Cancer Genome Atlas, Wang et al. showed that 17 of the 22 transcripts correlated with 
survival in 14 adult cancer types and that, in some cases, these correlations involved mul-
tiple cancers [48]. Finally, 16 of the transcripts showed associations with at least one of the 
ten known Cancer Hallmarks [59] and eight were associated with between five and nine. 
By way of comparison, the potent oncogenes KRAS and PIK3CA and the tumor suppressor 
TP53 are associated with five, six and eight of these Hallmarks, respectively. Collectively 
then, multiple HB-associated BYN transcripts were found to correlate quite strongly with 
survival not only in HB but in multiple other cancers. 
6. The Beginning of a Molecular Reconstruction of HB 
The findings summarized above should improve our understanding of the molecular 
pathogenesis of HB by shifting the causative focus from the Wnt/β-catenin and the Hippo 
pathways in general to a small subset of β-catenin-, Hippo pathway- and NFE2L2-regu-
lated target genes that are widely deregulated across multiple human cancers as well as 
HB. Toward this end, Wang et al. [48] noted that one of the above BYN group gene mem-
bers, namely serpine1, was not only the second most highly up-regulated (43.7-fold rela-
tive to liver) but was also the only gene whose human ortholog contained multiple Tcf/Lef 
(β-catenin), TEAD (YAP) and ARE (NFE2L2) elements in its proximal promoter. Serpin 
E1 protein levels were also highly elevated in Δ90) + YAPS127A + L30P/R34P tumors and 
Figure 1. The co-expression of ∆(90) β-catenin, YAPS127A and L30P/R34P induces HBs with widespread cyst formation
and necrosis. Low power (5×) images of H&E stained tumor HBs. The (left panel) shows the typical crowded fetal-like
appearance associated with the co-expression of ∆(90) β-catenin and YAPS127A [20,30,35]. The (right panel) shows a tumor
generated by the combined over-expression of ∆(90) β-catenin + YAPS127A + R34P. Note the cysts and adjacent regions of
widespread necrosis (asterisk). See [48] for additional, higher-power H&E-stained images of the crowded fetal morphology
(Reprinted with permission from ref. [48]. Copyright 2021 Children’s Hospital of Pittsburgh of UPMC).
Unexpectedly, Wang et al. [48] also found that any two combinations of ∆(90)β-catenin,
YAPS127A and L30P or R34P were tumorigenic, although the entire triad was needed to
promote cystogenesis, necrosis and accelerated growth. This indicated that, rather than
simply facilitating tumor growth by creating a more conducive environment [50,51,55],
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NFE2L2 mutants were directly oncogenic in their own right and equal to that of either ∆(90)
or YAPS127A when expressed in a pair-wise manner. This finding provided a feasible and
testable explanation for the high rates of NFE2L2 gene mutation or copy number variation
in HBs and other cancers by suggesting that HBs lacking one of the signature β-catenin or
Hippo pathway lesions might instead rely on NFE2L2 dysregulation.
Unsurprisingly, tumors generated by either the full complement of ∆(90) YAPS127A
and L30P/R34P mutants, or any two combinations of the three oncoproteins, possessed
distinct metabolic, biochemical and molecular signatures [48]. In the latter case, each of the
five possible tumor groups differed from one another by 821–4676 transcripts. Surprisingly,
some of these tumors thus differ from one another to a greater degree than do some mutant
β-catenin, +YAPS127A-generated HBs and control livers [35,46,48]. These distinct gene
expression repertoires, with limited amounts of overlap among groups, allowed Wang et al.
to identify transcripts specifically regulated by each oncoprotein as well as a common
subset of 41 so-called “BYN” transcripts shared among all tumor cohorts and postulated to
participate in a common transformation pathway [48].
Wang et al. [48] made several sassumptions in further refining the BYN subset to
its most basic core elements. First, they eliminated 12 transcripts that were not always
deregulated in the same direction in all tumor groups. An additional seven were eliminated
as they were not deregulated in all tumors generated from the β-catenin mutants studied
by Zhang et al. [20] or in an independently derived set of slowly growing ∆(90) + YAPS127A
HBs generated in mice with hepatocyte-specific knockout of myc and/or the myc-related
transcription factor chrebp [35,36]. The remaining 22 transcripts were thus posited to encode
a common set of factors mediating transformation but having little relevance to tumor
initiation or growth rates, histology or specific metabolic signatures.
Several features of the above 22 transcripts supported the notion that they were highly
relevant to HB pathogenesis. First, ten transcripts perfectly identified a high-risk category
of human HBs that had been previously stratified by two other groups based on expression
differences of 16 or four transcript sets [43,56]. None of the three gene sets contained
any common elements, thereby suggesting that the combined group of 30 transcripts
might be particularly useful for HB prognostication. Second, using data from The Cancer
Genome Atlas, Wang et al. showed that 17 of the 22 transcripts correlated with survival
in 14 adult cancer types and that, in some cases, these correlations involved multiple
cancers [48]. Finally, 16 of the transcripts showed associations with at least one of the ten
known Cancer Hallmarks [59] and eight were associated with between five and nine. By
way of comparison, the potent oncogenes KRAS and PIK3CA and the tumor suppressor
TP53 are associated with five, six and eight of these Hallmarks, respectively. Collectively
then, multiple HB-associated BYN transcripts were found to correlate quite strongly with
survival not only in HB but in multiple other cancers.
6. The Beginning of a Molecular Reconstruction of HB
The findings summarized above should improve our understanding of the molecular
pathogenesis of HB by shifting the causative focus from the Wnt/β-catenin and the Hippo
pathways in general to a small subset of β-catenin-, Hippo pathway- and NFE2L2-regulated
target genes that are widely deregulated across multiple human cancers as well as HB.
Toward this end, Wang et al. [48] noted that one of the above BYN group gene members,
namely serpine1, was not only the second most highly up-regulated (43.7-fold relative
to liver) but was also the only gene whose human ortholog contained multiple Tcf/Lef
(β-catenin), TEAD (YAP) and ARE (NFE2L2) elements in its proximal promoter. Serpin E1
protein levels were also highly elevated in ∆90) + YAPS127A + L30P/R34P tumors and both
plasma and cyst fluid from tumor-bearing mice contained increased levels of serpin E1.
Although classically associated with fibrinolysis, serpin E1, also known as plasmino-
gen activator inhibitor 1, plays numerous ancillary roles in tumor growth, matrix remodel-
ing, angiogenesis and metastasis [60]. It was also one of the transcripts mentioned in the
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above section whose deregulation was highly predictive of survival in HB and six different
adult cancer types [48].
Interestingly, elevated plasma levels of serpin E1 have been reported in patients with
polycystic ovary syndrome, and ovary-specific serpin E1 over-expression in mice is highly
cystogenic [61,62]. Therefore, hypothesizing that serpin E1 might be able to at least partially
substitute for L30P/R34P, Wang et al. [48] found that its co-expression with ∆(90) and
YAPS127A did not alter tumor growth rate or induce cysts but did promote widespread
necrosis. Wang et al. [48] therefore hypothesized that serpin E is likely to be only one of
several (if not all) BYN members that cross-talk and cooperate to impart both common and
unique features to different tumor cohorts.
7. Remaining Questions
The recent work of Zhang et al. and Wang et al. [20,48] discussed here raises a number
of additional points and questions that should now be readily addressable. For example, it
suggests that the ultimate behavior, appearance and transcriptional environment of any
given HB are likely to be a consequence of the integrated transcriptional output of at least
two of three pathways that are deregulated by the oncogenic activation of Wnt/β-catenin,
Hippo and NFE2L2 signaling. Since all three factors control distinct but overlapping
transcription programs and since the output of the β-catenin pathway is highly mutant-
dependent, might it be possible that additional subtleties in tumor appearance and behavior
are mediated through equally subtle differences in the nature of the defects affecting Hippo
and NFE2L2 signaling? Are certain β-catenin mutations, certain pro-oncogenic defects
in the Hippo signaling pathway and certain NFE2L2 mutations more or less likely to be
associated with one another and, if so, why? Can any of the three gene sets now having
been described as being predictive of HB patient survival [34,43,48] be used collectively
or in a more sophisticated way to permit increased prognostic power and/or therapeutic
design? Finally, how do individual members of the BYN transcript family cooperate with
one another to recapitulate any or all of the features of HB?
Sekiguchi et al. recently employed a multi-omics approach to classify 59 HBs [63],
and showed that epigenetic changes are not only widespread but may also contribute
to heterogeneous HB appearances and clinical behaviors. 56 of the tumors contained
β-catenin mutations and an additional four contained APC gene mutations (i.e., a 100%
incidence of Wnt/β-catenin/APC pathway dysregulation). While no mention was made
regarding Hippo or NFE2L2 pathway deregulation, 31% of the tumors showed whole-arm
amplification of chromosome 2q, which encodes NFE2L2. Interestingly, Sekiguchi et al.
identified three distinct tumor cohorts groups (E1, E2 and F) based upon the genome-wide
methylation patterns of 39 of the tumors, with the E1 and E2 groups being associated with
an inferior overall prognosis. The most differentially expressed hypomethylated gene in
these cohorts was NQO1, a common and well-characterized NFE2L2 target [64]. Although
difficult to correlate with our own previously reported findings [20,48], these recent results
do raise the possibility that different β-catenin mutations, perhaps in combination with dif-
ferential dysregulation of the Hippo and/or NFE2L2 pathways, might alter the expression
of the various methylases and demethylases that collectively regulate the HB transcriptome.
Similarly altered expression of micro-RNAs and long, non-coding RNAs could conceivably
contribute to HB gene expression profiles post-transcriptionally as well [65,66].
8. Conclusions
The work summarized in this review addresses several long-standing questions that
have confronted those who study HB and its pathogenesis. Among the most pressing
is how to explain the well-known histologic diversity of this genetically monotonous
cancer. It is now apparent that even subtle variations in β-catenin mutations, indeed even
those involving the same codon, can exert significant influence over tumor growth rates,
histology and transcriptional profiles, with each mutation regulating both common and
unique subsets of target genes in ways that are complex and still poorly understood [48].
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Another question is the nature of the underlying oncogenic underpinnings of the ~50% of
HBs lacking concurrent mutation/dysregulation of both β-catenin and Hippo pathways.
NFE2L2, a transcription factor long been thought to initiate a broad range of oxidative
and electrophilic stress responses, is now known to be directly oncogenic and to cooperate
with either or both of the other two pathways to initiate de novo tumorigenesis, accelerate
its progression, alter its metabolic and transcriptional features and impart new features.
Finally, the large number of genes that are deregulated in each of these individual tumor
cohorts relative to the normal liver has made it difficult to separate those that are the
most critical for transformation from those with either ancillary roles or none at all. The
identification of a small common subset of so-called BYN genes from the several thousand
that are deregulated in any given tumor provides a readily manageable number that avail
themselves to more in-depth scrutiny in future studies. The fact that the expression of
virtually all the genes in this collection correlate with adverse prognosis in HB or other
human cancers (or, in some cases, multiple cancers) is testimony to the underlying role(s)
they seem likely to play.
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